|Announcement regarding the Advanced Therapy Access Program
Since 2007, 280 patients with chemotherapy refractory cancer have been treated with oncolytic viruses in the Advanced Therapy Access Program (ATAP). Safety of the therapy has been good and published analyses of the data suggest that many patients may have benefited from the treatment.
Oncos Therapeutics (Helsinki, Finland) proceeds with development of the therapy and will focus on clinical studies starting 1.1.2012. In medicine, clinical studies are needed to formally demonstrate the safety and efficacy of new drugs, and to obtain market approval. Unfortunately, no new patients will be enrolled in ATAP for the time being. Patients already in the program can continue to receive treatment on a personalized basis as designed by their oncologist. Information on clinical trials will be available as soon as they open.
We thank the patients who have been part of ATAP and have therefore helped move this promising therapy forward.